Logo
x

Search category

Subscribe Now

All Posts by Date

Urovant's Gemtesa (vibegron) Receives the US FDA's Approval for Overactive Bladder

Urovant's Gemtesa (vibegron) Receives the US FDA's Approval for Overactive Bladder

  • December 23, 2020
Janssen's Darzalex (daratumumab) Receives Health Canada Approval for the Treatment of Multiple Myeloma

Janssen's Darzalex (daratumumab) Receives Health Canada Approval for the Treatment of Multiple Myeloma

  • December 23, 2020
Voyager Therapeutics Provides Update on NBIB-1817 (VY-AADC) Program to Treat Parkinson Disease

Voyager Therapeutics Provides Update on NBIB-1817 (VY-AADC) Program to Treat Parkinson Disease

  • December 23, 2020
Janssen Initiates Rolling Submission of BLA to US FDA of Autoleucel (cilta-cel) to Treat Multiple Myeloma

Janssen Initiates Rolling Submission of BLA to US FDA of Autoleucel (cilta-cel) to Treat Multiple Myeloma

  • December 23, 2020
Ocular Therapeutix Reports sNDA Submission of Dextenza (dexamethasone ophthalmic insert) to the US FDA for Ocular Itching

Ocular Therapeutix Reports sNDA Submission of Dextenza (dexamethasone ophthalmic insert) to the US FDA for Ocular Itching

  • December 23, 2020
AMO Pharma Initiates P-II REACH-CDM study of AMO-02 (tideglusib) to treat Congenital Myotonic Dystrophy

AMO Pharma Initiates P-II REACH-CDM study of AMO-02 (tideglusib) to treat Congenital Myotonic Dystrophy

  • December 23, 2020
Image

Stay Connected

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2023 PharmaShots - All Rights Reserved.